MedTrace Logo

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

NCT04645550 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-03-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy

Conditions

  • Cirrhosis
  • Splenectomy; Status
  • Venous Thrombosis
  • Hypertension, Portal

Interventions

DRUG

Apixaban

From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.

DRUG

Warfarin

From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.

DRUG

Aspirin

From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.

DRUG

Dipyridamole

From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

DRUG

Low molecular weight heparin

From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Sponsors & Collaborators

  • Northern Jiangsu People's Hospital

    lead OTHER

Principal Investigators

  • Dou-Sheng Bai Bai, MD · Clinical Medical College of Yangzhou University

  • Guo-Qing Jiang, MD · Clinical Medical College of Yangzhou University

  • Sheng-Jie Jin, MD · Clinical Medical College of Yangzhou University

  • Bao-Huan Zhou, MS · Clinical Medical College of Yangzhou University

  • Tian-Ming Gao, MS · Clinical Medical College of Yangzhou University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645550 on ClinicalTrials.gov